stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Debt to equity
Viking Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.4×, up 0.4× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.4× (fiscal 2016) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.3× | (36.95%) |
| FY2016 | 0.4× | 64.84% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.4× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
73
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CELC Celcuity, Inc. compare | −58.9× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 0.0× |
| ELVN Enliven Therapeutics, Inc. compare | 0.0× |
| XENE Xenon Pharmaceuticals Inc. compare | 0.0× |
| PBLS Parabilis Medicines, Inc. compare | 0.0× |
| IRON Disc Medicine, Inc. compare | 0.1× |
| DYN Dyne Therapeutics, Inc. compare | 0.3× |
| VKTX Viking Therapeutics, Inc. | 0.4× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.7× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)